| Schedule of Financial Information Operating Segment |
The
following table presents selected financial information with respect to the Company’s single operating segment and its significant
segment expenses for the three and six months ended December 31, 2025 and 2024:
Schedule
of Financial Information Operating Segment
| C |
|
|
1 |
|
|
|
2 |
|
| |
|
Three Months Ended
December 31,
|
|
| |
|
2025 |
|
|
2024 |
|
| Pre-clinical and clinical studies |
|
$ |
928,288 |
|
|
$ |
455,039 |
|
| Contract manufacturing |
|
|
47,835 |
|
|
|
435,999 |
|
| Consultants and other research and development |
|
|
188,614 |
|
|
|
329,497 |
|
| Compensation and related benefits |
|
|
632,123 |
|
|
|
423,899 |
|
| Professional and consultant fees |
|
|
478,283 |
|
|
|
196,282 |
|
| Stock-based compensation expense |
|
|
198,530 |
|
|
|
564,333 |
|
| Directors’ and officers’ insurance |
|
|
113,518 |
|
|
|
122,983 |
|
| Facilities, fees and other related costs |
|
|
32,719 |
|
|
|
60,119 |
|
| Interest expense |
|
|
17,439 |
|
|
|
59,696 |
|
| Interest income |
|
|
(85,410 |
) |
|
|
(7,067 |
) |
| Grant income |
|
|
(552,576 |
) |
|
|
(177,703 |
) |
| Other |
|
|
34 |
|
|
|
(47 |
) |
| Net loss |
|
$ |
(1,999,397 |
) |
|
$ |
(2,463,030 |
) |
| C |
|
|
168,420 |
|
|
|
651,465 |
|
| |
|
Six Months Ended
December 31,
|
|
| |
|
2025 |
|
|
2024 |
|
| Pre-clinical
and clinical studies |
|
$ |
1,335,200 |
|
|
$ |
1,288,900 |
|
| Contract
manufacturing |
|
|
168,420 |
|
|
|
651,465 |
|
| Consultants
and other research and development |
|
|
471,108 |
|
|
|
595,029 |
|
| Compensation
and related benefits |
|
|
953,459 |
|
|
|
730,512 |
|
| Professional
and consultant fees |
|
|
1,188,477 |
|
|
|
512,076 |
|
| Stock-based
compensation expense |
|
|
436,174 |
|
|
|
851,253 |
|
| Directors’
and officers’ insurance |
|
|
223,847 |
|
|
|
240,141 |
|
| Facilities,
fees and other related costs |
|
|
103,485 |
|
|
|
130,899 |
|
| Interest
expense |
|
|
34,878 |
|
|
|
119,393 |
|
| Interest
income |
|
|
(195,026 |
) |
|
|
(33,073 |
) |
| Grant
income |
|
|
(562,401 |
) |
|
|
(423,065 |
) |
| Other |
|
|
130 |
|
|
|
236 |
|
| Net
loss |
|
$ |
(4,157,751 |
) |
|
$ |
(4,663,766 |
) |
|